Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity Presented ByDr Xin Gao, Massachusetts General Hospital, MA, USA TrialPhase 2, ARDENT ConferenceASCO GU 2022 TypePeer-reviewed article 8 April 2022 11:21